FDA Approves Nexus Pharmaceuticals' Methylene Blue Injection for Acquired Methemoglobinemia
• The FDA has approved Nexus Pharmaceuticals' Methylene Blue Injection, USP, for treating acquired methemoglobinemia, a rare blood disorder.
• Methylene Blue functions as an oxidation-reduction agent, converting the oxidized form of hemoglobin (Fe3+) to its reduced state (Fe2+), enhancing oxygen binding.
• The newly approved formulation will be available in single-dose vials, strengthening the supply of this critical medication for affected patients.
• Acquired methemoglobinemia can result from exposure to certain medications and leads to symptoms like cyanosis, headache, and shortness of breath.
© Copyright 2025. All Rights Reserved by MedPath